NCT02722161View on ClinicalTrials.gov

Olmutinib (BI 1482694) ADME Study

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Healthy
Interventions
DRUG

[14C]BI 1482694

Trial Locations (1)

Unknown

1370.7.31001 Boehringer Ingelheim Investigational Site, Zuidlaren

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY